TP53 and osteosarcoma: Indeed, the deletion of the transcription factor ETS2 in conditional osteoblast mutant p53 mice reduces the expression of a panel of 24 snoRNAs and reverses the metastatic phenotype of mutant p53 without affecting osteosarcoma development.